PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
4142788-1	1974	The tumorigenic EPO clonal cell line, derived from a methylcholanthrene-induced murine sarcoma, was exposed to increasing concentrations of actinomycin D and gave rise to a subline, resistant to 0.02 mug of actinomycin D per ml of medium, which was designated EPO/ADj.	Dactinomycin	140-153	erythropoietin	Mus musculus	16-19	
7448391-3	1980	It is known that inoculation of mice with low doses of actinomycin D (Act D) results in a specific suppression of erythropoiesis without impairing the endogenous erythropoietin production.	Dactinomycin	55-68	erythropoietin	Mus musculus	162-176	
476265-0	1979	Further investigations about actinomycin D action on mouse erythropoietin responsive cell.	Dactinomycin	29-42	erythropoietin	Mus musculus	59-73	
476265-3	1979	The same relation appeared in the action of various Actinomycin D doses on the response to erythropoietin in hypertransfused-mice.	Dactinomycin	52-65	erythropoietin	Mus musculus	91-105	
1657247-7	1991	The half-life for EPO receptor mRNA was approximately 75 minutes, as determined using the transcriptional inhibitor actinomycin D.	Dactinomycin	116-129	erythropoietin	Mus musculus	18-21	
4142788-5	1974	The morphology of cells changed with actinomycin-D-resistance: EPO/ADj cells were more spread and flattened and less overlapping than the original fibroblast-like EPO cells.	Dactinomycin	37-50	erythropoietin	Mus musculus	63-66	
4142788-5	1974	The morphology of cells changed with actinomycin-D-resistance: EPO/ADj cells were more spread and flattened and less overlapping than the original fibroblast-like EPO cells.	Dactinomycin	37-50	erythropoietin	Mus musculus	163-166